Where BeiGene Stands With Analysts
Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:
Novartis – BeiGene’s Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus…
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours.
Global Phase 3 Trial Of BeiGene’s PD-1 Inhibitor, Tislelizumab, In Combination With Chemotherapy Meets Primary Endpoint In First-Line Advanced Esophageal Squamous Cell Carcinoma
Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy
Safety profile for the combination consistent
The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer
BeiGene Ltd (NASDAQ:BGNE) shared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus…
BeiGene To Present Results From Phase 3 RATIONALE-309 Trial At ASCO Plenary Series
Progression-Free Survival Benefit of Tislelizumab in Combination with Chemotherapy Sustained at Median 15.5 Month Follow-up
Secondary Survival Endpoint Findings Were Consistent with Interim Analysis
CAMBRIDGE,
BeiGene’s Brukinsa Tops JNJ’s Imbruvica In Overall Response Rate In Leukemia Study
BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Key Takeaways:
BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law
The change could reduce the company’s threat of being forcibly delisted from the Nasdaq
By Doug Young